Vernal Keratoconjunctivitis Market Expected to Witness Robust Growth Through 2036 Driven by Emerging Immunomodulatory Therapies and Rising Disease Awareness | DelveInsight

DelveInsight's "Vernal Keratoconjunctivitis Market Insight, Epidemiology, and Market Forecast-2036" report provides a comprehensive understanding of Vernal Keratoconjunctivitis (VKC), including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, and commercial opportunities across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report evaluates disease burden, treatment landscape, market dynamics, and the impact of upcoming therapies expected to reshape the VKC market over the forecast period.

Vernal Keratoconjunctivitis is a chronic, severe allergic inflammatory disorder of the ocular surface that primarily affects children and adolescents. The disease can significantly impair quality of life and, if left untreated, may result in corneal damage and vision loss. Although topical antihistamines, mast cell stabilizers, corticosteroids, and immunomodulators remain the cornerstone of treatment, the limited availability of approved therapies creates substantial opportunities for novel targeted therapeutics. According to DelveInsight, the VKC market is expected to expand significantly through 2036 as innovative immunomodulatory agents advance through clinical development.

Key Takeaways from the Vernal Keratoconjunctivitis Market Report

• DelveInsight estimates that the Vernal Keratoconjunctivitis market across the 7MM was valued at nearly USD 1.5 billion in 2025 and is projected to reach approximately USD 4.2 billion by 2036, driven by increasing diagnosis, improved disease awareness, and the launch of emerging therapies.

• According to DelveInsight's analysis, the United States reported nearly 69,500 prevalent cases of Vernal Keratoconjunctivitis in 2025, with approximately 28,300 diagnosed prevalent cases.

• In the United States, approximately 85% of prevalent VKC cases occurred in males, while children and adolescents represented the largest affected patient population. Moderate disease severity accounted for the highest proportion of cases during 2025.

• Among the European countries, Italy accounted for the highest prevalence of Vernal Keratoconjunctivitis in 2025, while Japan represented another major patient population across the 7MM.

• VERKAZIA (cyclosporine ophthalmic emulsion) currently represents the primary approved therapy for Vernal Keratoconjunctivitis in the United States and Europe, while TALYMUS (tacrolimus ophthalmic suspension) remains approved in Japan for severe allergic conjunctival diseases, including VKC.

• The emerging pipeline includes promising therapies such as NTX-1024 (NexEos Bio) and iCo-008 (bertilimumab) (iCo Therapeutics), highlighting continued innovation despite the relatively limited development landscape.

Download the Vernal Keratoconjunctivitis Market report sample here:
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Vernal Keratoconjunctivitis Market

• Increasing awareness among ophthalmologists, improved diagnosis of severe ocular allergic diseases, expanding use of topical immunomodulators, and growing research into inflammatory pathways are expected to support continued market growth. Rising recognition of long-term complications associated with uncontrolled VKC has also increased the demand for steroid-sparing therapies capable of providing sustained disease control.

• The development of innovative biologics, targeted immunomodulators, and novel anti-inflammatory therapies is expected to transform the future treatment landscape. Although current management relies heavily on antihistamines, mast cell stabilizers, corticosteroids, cyclosporine, and tacrolimus, emerging pipeline therapies targeting eosinophilic inflammation offer the potential for improved efficacy and reduced long-term steroid exposure.
Vernal Keratoconjunctivitis Market Analysis
According to DelveInsight, the Vernal Keratoconjunctivitis market is anticipated to grow steadily throughout the forecast period owing to increasing disease awareness, improved diagnosis, greater adoption of immunomodulatory therapies, and the anticipated launch of emerging products. However, limited approved treatment options, absence of standardized treatment algorithms, and the relatively small development pipeline continue to represent significant unmet medical needs.

Read more about the Vernal Keratoconjunctivitis Market report:
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr
Vernal Keratoconjunctivitis Epidemiology Segmentation

• The Vernal Keratoconjunctivitis (VKC) epidemiology chapter provides comprehensive historical and forecasted patient population estimates across the seven major markets (7MM), including the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The report analyzes disease burden using multiple epidemiological segments to provide a detailed understanding of patient distribution, demographic trends, disease severity, and future commercial opportunities.

• According to DelveInsight's estimates, the United States reported nearly 69,500 prevalent cases of Vernal Keratoconjunctivitis in 2025, while the diagnosed prevalent population was estimated at approximately 28,300 cases. The patient population is expected to increase steadily throughout the forecast period due to improved disease awareness, earlier diagnosis, and increasing recognition of severe ocular allergic disorders.

• In the United States, male patients represented nearly 85% of prevalent cases in 2025, highlighting the marked gender predominance observed in VKC. Children and adolescents (0-20 years) accounted for the majority of cases, whereas adults represented a comparatively smaller patient population. Moderate disease constituted the largest proportion of prevalent cases, followed by mild and severe disease.

• Among the European countries, Italy accounted for the highest prevalence of Vernal Keratoconjunctivitis in 2025, while Spain reported the lowest patient population. In Japan, moderate disease represented approximately 60% of cases, with mild and severe disease each accounting for nearly 20% of the patient population.

The report evaluates the Vernal Keratoconjunctivitis patient population across several epidemiological segments, including:
• Total Prevalent Cases of Vernal Keratoconjunctivitis
• Total Diagnosed Prevalent Cases of Vernal Keratoconjunctivitis
• Gender-specific Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases (Palpebral, Bulbar, and Mixed)
• Severity-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases

Request a sample and discover the latest advancements in Vernal Keratoconjunctivitis treatment therapies, emerging drugs, epidemiology, and market forecasts:
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Vernal Keratoconjunctivitis Treatment Market

• The treatment of Vernal Keratoconjunctivitis aims to reduce ocular inflammation, relieve symptoms, prevent corneal complications, and preserve long-term visual function. Current therapeutic options include mast cell stabilizers, antihistamines, topical corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclosporine, tacrolimus, and other topical immunomodulators. In severe or refractory disease, supratarsal corticosteroid injections or surgical intervention may be considered to prevent permanent ocular damage.

• VERKAZIA (cyclosporine ophthalmic emulsion 0.1%) remains the primary approved therapy for Vernal Keratoconjunctivitis in the United States and Europe. As a calcineurin inhibitor, VERKAZIA directly targets ocular surface inflammation and allows long-term disease control while reducing dependence on corticosteroids and their associated adverse effects. In Japan, TALYMUS (tacrolimus ophthalmic suspension) has been approved for severe allergic conjunctival diseases, including VKC, since 2008.

• According to DelveInsight, the Vernal
Keratoconjunctivitis market is expected to witness substantial expansion throughout the forecast period owing to increasing diagnosis rates, improved physician awareness, expanding utilization of immunomodulatory therapies, and the anticipated introduction of novel pipeline products. Despite these advances, the absence of standardized treatment guidelines, limited approved therapies, and significant unmet clinical needs continue to create opportunities for future innovation.

Vernal Keratoconjunctivitis Emerging Drugs

The Vernal Keratoconjunctivitis pipeline remains relatively limited, with only a few therapies currently undergoing clinical development. Nevertheless, several innovative agents targeting eosinophilic inflammation and immune-mediated pathways have the potential to improve treatment outcomes for patients with severe disease.

Key emerging therapies include:
• NTX-1024 - NexEos Bio
• iCo-008 (bertilimumab) - iCo Therapeutics

NTX-1024, developed by NexEos Bio, is a topical ophthalmic therapy being investigated for eosinophilic conjunctivitis, including Vernal Keratoconjunctivitis. In February 2026, the company announced that the US FDA cleared its Investigational New Drug (IND) application, allowing initiation of a Phase II/III clinical trial evaluating NTX-1024 in patients with Vernal Keratoconjunctivitis.
iCo-008 (bertilimumab) is a human monoclonal antibody targeting eotaxin-1, a key chemokine involved in eosinophil recruitment during allergic inflammation. The therapy demonstrated favorable safety and tolerability during earlier clinical evaluations, and preparations for a Phase II clinical trial in Vernal Keratoconjunctivitis were announced in 2021. However, no additional clinical development updates have been reported by the company since then.

Vernal Keratoconjunctivitis Market Forecast:
https://www.delveinsight.com/insights/vernal-keratoconjunctivitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary of Vernal Keratoconjunctivitis
4. Key Events
5. Vernal Keratoconjunctivitis Epidemiology and Market Forecast Methodology
6. Vernal Keratoconjunctivitis Market Overview at a Glance
7. Disease Background and Overview: Vernal Keratoconjunctivitis
8. Treatment and Management Guidelines and Recommendations
9. Epidemiology and Patient Population of Vernal Keratoconjunctivitis in the 7MM
10. Patient Journey
11. Marketed Therapy
12. Emerging Therapies
13. Vernal Keratoconjunctivitis: Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Learn More About the Vernal Keratoconjunctivitis Market Report

Request a sample and discover the latest advancements in Vernal Keratoconjunctivitis treatment therapies, emerging drugs, epidemiology, and market forecasts:
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Contact Person:
Kirti Sharma
Email:
info@delveinsight.com
Phone:
+1-469-945-7679
Website:
https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.